Lv22
200 积分 2021-12-23 加入
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
5小时前
已完结
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
8小时前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
1天前
已完结
[Chinese expert consensus on standardized clinical application of 6-minute walk test]
22天前
已完结
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
2个月前
已完结
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
2个月前
已完结
Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis
3个月前
已完结
Heart failure with preserved ejection fraction
3个月前
已完结
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
3个月前
已完结
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
4个月前
已完结
皖公网安备34019202002308
